Compare Gilead Sciences, Inc. (GILD) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $149.95 (market cap $182.40B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.71 (market cap $47.61B). The key difference: Gilead Sciences, Inc. is far larger — about 3.8× iShares 20 Plus Year Treasury Bond ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| GILD | TLT | |
|---|---|---|
Market Cap | $182.40B | $47.61B |
Volume | 4,469,821 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $92.06 |
52-Week Low | $116.74 | $77.11 |
Typical Hold Time | 111 Days | 83 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.71 with a slight 0.73% daily gain amid a challenging bond market environment. The technical picture remains bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights Treasury yields reaching multi-decade highs, with the fund down 11% year-to-date and 46% over five years as investors face a new era of higher interest rates.
The outlook for TLT remains pressured by rising interest rates and inflation concerns, though current yields near 5.3% offer attractive income potential. Key risks include further Fed tightening and economic uncertainty, while potential catalysts could emerge from any moderation in inflation or economic slowdown that might prompt rate cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
